Liad Whatstein & Co. Law Office is predominantly involved in IP litigation, and the vast majority of its work is in the life sciences and healthcare sector. The firm acts for numerous global pharmaceutical companies in patent litigation and prosecution, as well as providing advice on regulatory and transactional issues. Lead partners Liad Whatstein and Amira Mangelus are ‘superb lawyers and advisors who are responsive to requests and work collaboratively’. They recently advised two major pharmaceutical clients on complex patent proceedings relating to a blockbuster anti-coagulant drug. Clients praise Whatstein’s ’depth of knowledge on both technical and legal issues’. Oren Weiner is a patent term extension specialist who also plays a key role in the practice.
Legal 500 redaktioneller Kommentar
- Profil
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘Liad Whatstein is a trusted advisor on life sciences patent matters. I have worked with Liad and his team for many years on matters involving common biopharma clients and his work has been consistently superb. He has a depth of knowledge on both technical and legal issues and works collaboratively with co-counsel on cross-border matters.’
‘I have worked with Liad Whatstein and Amira Mangelus over many years. They are superb lawyers and advisors. They are responsive to requests and work collaboratively. They are a pleasure to work with.’
Kernmandanten
- Novartis
- Sanofi
- Merck
- Pfizer
- Roche
- Bristol Myers
- Takeda
- Regeneron
- Abbott
- Bayer
Highlight-Mandate
- Advising some of the world’s major pharmaceutical companies, including Merck & Co., Sanofi, Pfizer, Novartis, BMS, Regeneron and Astellas as well as a host of smaller life science companies, on the local regulatory requirements of the Ministry of Health, including obtaining regulatory approvals for drugs, Data Exclusivity and strategic issues relating to the interplay and linkage between regulatory permits in Israel and worldwide and extension of patent term.
- Representing Sanofi and Regeneron in groundbreaking proceedings against Amgen’s patent claiming anti-PCSK9 antibodies.
- Advising the State of Israel on life science technologies developed in government hospitals and which are “service inventions” under Israeli law.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Liad Whatstein; Amira Mangelus
Weitere Kernanwält*innen
Oren Weiner